# Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome

> **NCT02175173** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 707 (actual)

## Conditions studied

- Lennox-Gastaut Syndrome

## Interventions

- **DRUG:** Rufinamide

## Key facts

- **NCT ID:** NCT02175173
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-13
- **Primary completion:** 2022-11-02
- **Final completion:** 2022-11-02
- **Target enrollment:** 707 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02175173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02175173, "Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02175173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*